… Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm … of Imatinib initially as
salvage therapy in 2001 and subsequently as front line therapy revolutionized CML therapy, …

… , S.; Iacobucci, I.; De Vivo, A.; Testoni, N.; Castagnetti, F.; Gugliotta, G.; et al. Effects and
outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid …

… The first trial with imatinib, a phase I study with poor risk CML patients, started in 1998. The
stunning results convinced even skeptics that further studies were indicated. In 1999, a group …

… Real-world evidence from low- and middle-income countries demonstrated that a decreased
adherence to imatinib treatment was associated with lower 10-year event-free survival [37]. …

… Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year
survival results of the randomized CML study IV and impact of non-CML determinants. …

… Do we need to increase the sensitivity of detection of BCR-… identify the patients who would
likely remain in treatment-free … chronic myeloid leukemia (CML) were treated with imatinib in …

… with chronic myeloid leukemia (CML) has drastically changed following the introduction of
different tyrosine kinase inhibitors (TKIs). In particular, long-term results obtained with imatinib, …

… Not Have Favorable Response to Imatinib; NCT01593254) is the first and only prospective
… in patients with lack of EMR to first-line imatinib. Here we present the first results of this study, …

… Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the
randomized BFORE trial. J Clin Oncol. 2018; 36(3): 231–237, doi: 10.1200/JCO.2017.74.7162, …

… In this study we try to assess adherence of CML patients to imatinib in Middle Euphrates
region of Iraq.This study can … Do you sometimes forget to take your medication? …